← Leaderboards
Erica Ollmann Saphire
Scripps Research Institute
$52,684,297
Attributed
$57,669,703
Total exposure
38
Grants
34
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.2M · FY2006–25$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$127,236,290 · 40
By mechanism
U19$95,600,275 · 7
R01$17,919,547 · 5
U01$4,781,497 · 2
P01$4,689,768 · 1
R21$2,607,574 · 5
R56$1,343,398 · 2
Top collaborators
- M. Javad Aman6 shared
- William R Schief6 shared
- Toshiaki Maruyama1 shared
- Matteo Porotto1 shared
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesVirusViralEbola VirusStructureGlycoproteinsImmunotherapeutic AgentViral Hemorrhagic FeversDisease OutbreaksComplexEpitopesProteinsFilovirusVaccinesMapsCellsStructural BiologyResourcesResearch PersonnelMonoclonal AntibodiesInnovationInfectionNeutralizing AntibodySuccess
Grant awards (106)
Filovirus nucleocapsid assembly, caught in the act, by in situ structural biology$228,750
R21 · FY2025 · AI · contact PI
What is the human antibody response to measles virus vaccination?$221,888
R21 · FY2025 · AI · contact PI
Thermostable measles fusion glycoprotein as a new vaccine strategy$883,864
R56 · FY2024 · AI
Development of Neutralizing Antibodies to Machupo Virus$280,769
R41 · FY2024 · AI
What is the human antibody response to measles virus vaccination?$274,500
R21 · FY2024 · AI · contact PI
Filovirus nucleocapsid assembly, caught in the act, by in situ structural biology$274,500
R21 · FY2024 · AI · contact PI
Structure of the SARS-CoV-2 Nucleocapsid: building block to viral capsid$229,720
R21 · FY2024 · AI · contact PI
Consortium for Immunotherapeutics against Emerging Viral Threats$7,006,270
U19 · FY2023 · AI · contact PI
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses$2,270,866
U19 · FY2023 · AI · contact PI
Integrative Immunogen Design and Testing$2,060,891
P01 · FY2023 · AI · contact PI
Structure of the SARS-CoV-2 Nucleocapsid: building block to viral capsid$285,857
R21 · FY2023 · AI · contact PI
Administrative Core$218,786
U19 · FY2023 · AI · contact PI
Consortium for Immunotherapeutics against Emerging Viral Threats$7,020,842
U19 · FY2022 · AI · contact PI
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses$2,209,674
U19 · FY2022 · AI · contact PI
Administrative Core$328,123
U19 · FY2022 · AI · contact PI
Consortium for Immunotherapeutics against Emerging Viral Threats$7,065,330
U19 · FY2021 · AI · contact PI
Integrative Immunogen Design and Testing$2,628,877
P01 · FY2021 · AI · contact PI
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses$2,222,178
U19 · FY2021 · AI · contact PI
Consortium for Immunotherapeutics against Emerging Viral Threats$1,903,653
U19 · FY2021 · AI · contact PI
Rationally Designed Pan-Ebolavirus Vaccine$886,705
R01 · FY2021 · AI
Administrative Core$319,861
U19 · FY2021 · AI · contact PI
Rationally Designed Pan-Ebolavirus Vaccine$166,279
R01 · FY2021 · AI
Consortium for Immunotherapeutics against Emerging Viral Threats$7,143,424
U19 · FY2020 · AI · contact PI
Consortium for Immunotherapeutics against Emerging Viral Threats$2,688,763
U19 · FY2020 · AI · contact PI
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses$2,406,479
U19 · FY2020 · AI · contact PI
Rationally Designed Pan-Ebolavirus Vaccine$1,240,735
R01 · FY2020 · AI
Administrative Core$266,823
U19 · FY2020 · AI · contact PI
Consortium for Immunotherapeutics against Emerging Viral Threats$7,168,390
U19 · FY2019 · AI · contact PI
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses$2,972,368
U19 · FY2019 · AI · contact PI
Rationally Designed Pan-Ebolavirus Vaccine$1,246,581
R01 · FY2019 · AI
Administrative Core$292,297
U19 · FY2019 · AI · contact PI
Function and assembly of the Ebola virus nucleocapsid$276,728
R01 · FY2019 · AI · contact PI
Function and assembly of the Ebola virus nucleocapsid$226,977
R01 · FY2019 · AI · contact PI
Consortium for Immunotherapeutics Against Viral Hemorrhagic Fevers$5,407,592
U19 · FY2018 · AI · contact PI
Rationally Designed Pan-Ebolavirus Vaccine$1,372,407
R01 · FY2018 · AI
Immunotherapeutics against Ebola (Zaire) virus$1,366,422
U19 · FY2018 · AI · contact PI
Mechanistic Structural Biology Core$857,485
U19 · FY2018 · AI · contact PI
Function and assembly of the Ebola virus nucleocapsid$503,705
R01 · FY2018 · AI · contact PI
Administrative Core$469,618
U19 · FY2018 · AI · contact PI
Consortium for Immunotherapeutics Against Viral Hemorrhagic Fevers$6,084,280
U19 · FY2017 · AI · contact PI
Rationally Designed Pan-Ebolavirus Vaccine$1,691,927
R01 · FY2017 · AI
Immunotherapeutics against Ebola (Zaire) virus$1,617,150
U19 · FY2017 · AI · contact PI
Mechanistic Structural Biology Core$844,400
U19 · FY2017 · AI · contact PI
Function and assembly of the Ebola virus nucleocapsid$503,705
R01 · FY2017 · AI · contact PI
Administrative Core$288,749
U19 · FY2017 · AI · contact PI
Consortium for Immunotherapeutics Against Viral Hemorrhagic Fevers$6,522,487
U19 · FY2016 · AI · contact PI
Immunotherapeutics against Ebola (Zaire) virus$1,425,663
U19 · FY2016 · AI · contact PI
Administrative Core$845,080
U19 · FY2016 · AI · contact PI
Mechanistic Structural Biology Core$593,092
U19 · FY2016 · AI · contact PI
Function and assembly of the Ebola virus nucleocapsid$503,705
R01 · FY2016 · AI · contact PI
Interpreting a hard-won structure of the arenavirus prefusion glycoprotein$236,875
R21 · FY2016 · AI · contact PI
Consortium for Immunotherapeutics Against Viral Hemorrhagic Fevers$5,557,936
U19 · FY2015 · AI · contact PI
Immunotherapeutics against Ebola (Zaire) virus$1,380,740
U19 · FY2015 · AI · contact PI
Mechanistic Structural Biology Core$572,301
U19 · FY2015 · AI · contact PI
Function and assembly of the Ebola virus nucleocapsid$459,534
R56 · FY2015 · AI · contact PI
Interpreting a hard-won structure of the arenavirus prefusion glycoprotein$299,884
R21 · FY2015 · AI · contact PI
Administrative Core$139,855
U19 · FY2015 · AI · contact PI
Consortium for Immunotherapeutics Against Viral Hemorrhagic Fevers$5,997,620
U19 · FY2014 · AI · contact PI
Immunotherapeutics against Ebola (Zaire) virus$1,259,802
U19 · FY2014 · AI · contact PI
Mechanistic Structural Biology Core$720,850
U19 · FY2014 · AI · contact PI
Analysis of immunotherapeutics to native Marburg virus epitopes$671,896
R01 · FY2014 · AI · contact PI
STRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITE$412,920
R01 · FY2014 · AI · contact PI
Administrative Core$145,026
U19 · FY2014 · AI · contact PI
Analysis of immunotherapeutics to native Marburg virus epitopes$630,395
R01 · FY2013 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$416,631
R01 · FY2013 · AI · contact PI
STRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITE$388,561
R01 · FY2013 · AI · contact PI
STRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITE$654,731
R01 · FY2012 · AI · contact PI
Analysis of immunotherapeutics to native Marburg virus epitopes$575,523
R01 · FY2012 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$443,226
R01 · FY2012 · AI · contact PI
STRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITE$646,150
R01 · FY2011 · AI · contact PI
Analysis of immunotherapeutics to native Marburg virus epitopes$504,621
R01 · FY2011 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$443,226
R01 · FY2011 · AI · contact PI
ANTIBODY GLYCOPROTEIN COMPLEXES FROM VIRAL HEMORRHAGIC FEVERS$1,368
P41 · FY2011 · RR · contact PI
MAPPING ANTIBODY EPITOPES ON VIRAL HEMORRHAGIC FEVERS BY SAXS$279
P41 · FY2011 · RR · contact PI
ERICA OLLMANN SAPHIRE PRT TIME$279
P41 · FY2011 · RR · contact PI
Immunotherapeutics vs Ebola Sudan: Development, Structural & Functional Analysis$740,922
U01 · FY2010 · AI · contact PI
STRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITE$701,172
R01 · FY2010 · AI · contact PI
Immunotherapeutics against Marburg: Development, structural & functional anaylsis$629,885
U01 · FY2010 · AI · contact PI
Analysis of immunotherapeutics to native Marburg virus epitopes$535,157
R01 · FY2010 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$446,760
R01 · FY2010 · AI · contact PI
ANTIBODY GLYCOPROTEIN COMPLEXES FROM VIRAL HEMORRHAGIC FEVERS$1,349
P41 · FY2010 · RR · contact PI
ERICA OLLMANN SAPHIRE PRT TIME$1,349
P41 · FY2010 · RR · contact PI
MAPPING ANTIBODY EPITOPES ON VIRAL HEMORRHAGIC FEVERS BY SAXS$346
P41 · FY2010 · RR · contact PI
Immunotherapeutics vs Ebola Sudan: Development, Structural & Functional Analysis$747,538
U01 · FY2009 · AI · contact PI
Immunotherapeutics against Marburg: Development, structural & functional anaylsis$629,885
U01 · FY2009 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$451,272
R01 · FY2009 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$10,558
R01 · FY2009 · AI · contact PI
ANTIBODY-GLYCOPROTEIN COMPLEXES FROM VIRAL HEMORRHAGIC FEVERS$213
P41 · FY2009 · RR · contact PI
ANTIBODY GLYCOPROTEIN COMPLEXES FROM VIRAL HEMORRHAGIC FEVERS$213
P41 · FY2009 · RR · contact PI
MAPPING ANTIBODY EPITOPES ON VIRAL HEMORRHAGIC FEVERS BY SAXS$213
P41 · FY2009 · RR · contact PI
ERICA OLLMANN SAPHIRE PRT TIME$213
P41 · FY2009 · RR · contact PI
Immunotherapeutics vs Ebola Sudan: Development, Structural & Functional Analysis$728,213
U01 · FY2008 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$451,272
R01 · FY2008 · AI · contact PI
ANTIBODY-GLYCOPROTEIN COMPLEXES FROM VIRAL HEMORRHAGIC FEVERS$2,107
P41 · FY2008 · RR · contact PI
MAPPING ANTIBODY EPITOPES ON VIRAL HEMORRHAGIC FEVERS BY SAXS$184
P41 · FY2008 · RR · contact PI
ERICA OLLMANN SAPHIRE PRT TIME$184
P41 · FY2008 · RR · contact PI
Immunotherapeutics vs Ebola Sudan: Development, Structural & Functional Analysis$648,467
U01 · FY2007 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$451,272
R01 · FY2007 · AI · contact PI
ERICA OLLMANN SAPHIRE PRT TIME$1,388
P41 · FY2007 · RR · contact PI
ANTIBODY-GLYCOPROTEIN COMPLEXES FROM VIRAL HEMORRHAGIC FEVERS$993
P41 · FY2007 · RR · contact PI
Immunotherapeutics vs Ebola Sudan: Development, Structural & Functional Analysis$656,587
U01 · FY2006 · AI · contact PI
EBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSIS$464,750
R01 · FY2006 · AI · contact PI
ERICA OLLMANN SAPHIRE PRT TIME$2,565
P41 · FY2006 · RR · contact PI
STRUCTURAL ANALYSIS OF EBOLA VIRUS GLYCOPROTEINS$219
P41 · FY2006 · RR · contact PI
Structural Studies of Ebola Viral Pathogenesis$277,800
R21 · FY2003 · AI
Structural Studies of Ebola Viral Pathogenesis$277,800
R21 · FY2002 · AI